ArticleThe Journal of clinical investigation2011
S6 kinase 1 is required for rapamycin-sensitive liver proliferation after mouse hepatectomy.
Article in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 77 citations in OpenAlex.
- Pregnane X receptor-mediated liver growth: a controlled clinical trial in healthy volunteers and identification of the role of AKT-MTOR pathway in mouse.Archives of toxicology · 2026Article
- Ribosome biogenesis: A central player in liver diseases.Genes & diseases · 2025Review
- mRNA translational control of regeneration.Current opinion in genetics & development · 2025Review
- Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics.Signal transduction and targeted therapy · 2025Review
- Autophagy in Muscle Regeneration: Mechanisms, Targets, and Therapeutic Perspective.International journal of molecular sciences · 2024Review
- Using different zebrafish models to explore liver regeneration.Frontiers in cell and developmental biology · 2024Review
- The sensitivity of mTORC1 signaling activation renders tissue regenerative capacity.Cell regeneration (London, England) · 2023Article
- Mfap4: a promising target for enhanced liver regeneration and chronic liver disease treatment.NPJ Regenerative medicine · 2023Article
- Blocking autophagy with chloroquine aggravates lipid accumulation and reduces intracellular energy synthesis in hepatocellular carcinoma cells, both contributing to its anti-proliferative effect.Journal of cancer research and clinical oncology · 2022Article
- SHP2 inhibition enhances Yes-associated protein-mediated liver regeneration in murine partial hepatectomy models.JCI insight · 2022Article
- eIF3a regulation of mTOR signaling and translational control via HuR in cellular response to DNA damage.Oncogene · 2022Article
- Paligenosis: Cellular Remodeling During Tissue Repair.Annual review of physiology · 2022Review
- A narrative review of liver regeneration-from models to molecular basis.Annals of translational medicine · 2021Review
- Liver-specific deletion of mechanistic target of rapamycin does not protect against acetaminophen-induced liver injury in mice.Liver research (Beijing, China) · 2021Article
- Nutrient availability contributes to a graded refractory period for regeneration in Xenopus tropicalis.Developmental biology · 2021Article
- Liver homeostasis is maintained by midlobular zone 2 hepatocytes.Science (New York, N.Y.) · 2021Article
- Modulation of Autophagy: A Novel "Rejuvenation" Strategy for the Aging Liver.Oxidative medicine and cellular longevity · 2021Review
- Cell cycle regulation in NAFLD: when imbalanced metabolism limits cell division.Hepatology international · 2020Review
- mTOR Signaling at the Crossroad between Metazoan Regeneration and Human Diseases.International journal of molecular sciences · 2020Review
- mTORC2 Signaling Is Necessary for Timely Liver Regeneration after Partial Hepatectomy.The American journal of pathology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Rapamycin is an antibiotic inhibiting eukaryotic cell growth and proliferation by acting on target of rapamycin (TOR) kinase. Mammalian TOR (mTOR) is thought to work through 2 independent complexes to regulate cell size and cell replication, and these 2 complexes show differential sensitivity to rapamycin. Here we combine functional genetics and pharmacological treatments to analyze rapamycin-sensitive mTOR substrates that are involved in cell proliferation and tissue regeneration after partial hepatectomy in mice. After hepatectomy, hepatocytes proliferated rapidly, correlating with increased S6 kinase phosphorylation, while treatment with rapamycin derivatives impaired regeneration and blocked S6 kinase activation. In addition, genetic deletion of S6 kinase 1 (S6K1) caused a delay in S phase entry in hepatocytes after hepatectomy. The proliferative defect of S6K1-deficient hepatocytes was cell autonomous, as it was also observed in primary cultures and hepatic overexpression of S6K1-rescued proliferation. We found that S6K1 controlled steady-state levels of cyclin D1 (Ccnd1) mRNA in liver, and cyclin D1 expression was required to promote hepatocyte cell cycle. Notably, in vivo overexpression of cyclin D1 was sufficient to restore the proliferative capacity of S6K-null livers. The identification of an S6K1-dependent mechanism participating in cell proliferation in vivo may be relevant for cancer cells displaying high mTOR complex 1 activity and cyclin D1 accumulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.